Civitas drug for Parkinson's symptom wins $1M grant

06/19/2013 | American City Business Journals

The Michael J. Fox Foundation for Parkinson's Research awarded Civitas Therapeutics a $1 million grant to support a Phase II study of CVT-301, its lead drug candidate for intermittent debilitating motor fluctuations, which affect many patients with Parkinson's disease. The drug is an inhaled formulation of levodopa, whose approved indications include OFF episodes.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX